Third-line Therapy for Overactive Bladder in the Elderly: Nuances And considerations

Overview

Journal Neurourol Urodyn

Date 2022 Jun 1

PMID 35645033

Authors

Jacqueline Zillioux

Emily A Slopnick

Sandip P Vasavada

Affiliations

Soon will be listed here.

Abstract

Introduction: Overactive bladder (OAB) disproportionally affects older adults in both incidence and severity. OAB pharmacotherapy is often problematic in the elderly due to polypharmacy, adverse side effect profiles and contraindications in the setting of multiple comorbidities, and concerns regarding the risk of incident dementia with anticholinergic use. The burden of OAB in older patients coupled with concerns surrounding pharmacotherapy options should motivate optimization of nonpharmacologic therapies in this population. At the same time, several aspects of aging may impact treatment efficacy and decision-making. This narrative review critically summarizes current evidence regarding third-line OAB therapy use in the elderly and discusses nuances and treatment considerations specific to the population.

Methods: We performed an extensive, nonsystematic evidence assessment of available literature via PubMed on onabotulinumtoxinA (BTX-A), sacral neuromodulation, and percutaneous tibial nerve stimulation (PTNS) for OAB, with a focus on study in elderly and frail populations.

Results: While limited, available studies show all three third-line therapies are efficacious in older populations and there is no data to support one option over another. BTX-A likely has a higher risk of urinary tract infection and retention in older compared to younger populations, especially in the frail elderly. PTNS incurs the lowest risk, although adherence is poor, largely due to logistical burdens.

Conclusion: Advanced age and frailty should not preclude third-line therapy for refractory OAB, as available data support their efficacy and safety in these populations. Ultimately, treatment choices should be individualized and involve shared decision-making.

Citing Articles

Outcomes following intradetrusor onabotulinumtoxinA in a national cohort of nursing home residents.

Dreyfuss L, Nik-Ahd F, Wang L, Shatkin-Margolis A, Covinsky K, Boscardin W BJUI Compass. 2025; 6(1):e472.

PMID: 39877559 PMC: 11771503. DOI: 10.1002/bco2.472.

Sacral neuromodulation in nursing home residents: Predictors of success and complications in a national cohort of older adults.

Dreyfuss L, Nik-Ahd F, Wang L, Shatkin-Margolis A, Covinsky K, Boscardin W Neurourol Urodyn. 2024; 43(7):1534-1544.

PMID: 38624030 PMC: 11338736. DOI: 10.1002/nau.25465.

Enhancing surgical precision: unveiling the impact of preoperative colonoscopy in anal fistula patients.

Xu S, Zhang L, Li Z, Wang K, Liu F, Cao B BMC Gastroenterol. 2023; 23(1):442.

PMID: 38102560 PMC: 10722667. DOI: 10.1186/s12876-023-03066-x.

The impact of cognitive impairment in urologic implants: a narrative review.

Bryk D, Zillioux J, Kennady E, Sun F, Hasken W, Ortiz N Transl Androl Urol. 2023; 12(9):1426-1438.

PMID: 37814692 PMC: 10560334. DOI: 10.21037/tau-23-226.

Ninjin'yoeito Improves Genitourinary Symptoms in Patients With Frailty.

Okui N, Okui M Cureus. 2023; 15(6):e40767.

PMID: 37363115 PMC: 10285262. DOI: 10.7759/cureus.40767.

References

Peters K, Killinger K, Gilleran J, Boura J . Does patient age impact outcomes of neuromodulation?. Neurourol Urodyn. 2012; 32(1):30-6. DOI: 10.1002/nau.22268. View

Griffiths D, Tadic S, Schaefer W, Resnick N . Cerebral control of the lower urinary tract: how age-related changes might predispose to urge incontinence. Neuroimage. 2009; 47(3):981-6. PMC: 2719686. DOI: 10.1016/j.neuroimage.2009.04.087. View

Vurture G, Peyronnet B, Feigin A, Biagioni M, Gilbert R, Rosenblum N . Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease. Neurourol Urodyn. 2018; 37(8):2669-2677. DOI: 10.1002/nau.23717. View

Vollstedt A, Gilleran J . Update on Implantable PTNS Devices. Curr Urol Rep. 2020; 21(7):28. DOI: 10.1007/s11934-020-00980-5. View

Sakakibara R, Panicker J, Fowler C, Tateno F, Kishi M, Tsuyuzaki Y . Vascular incontinence: incontinence in the elderly due to ischemic white matter changes. Neurol Int. 2012; 4(2):e13. PMC: 3490472. DOI: 10.4081/ni.2012.e13. View

Laudano M, Seklehner S, Sandhu J, Reynolds W, Garrett K, Milsom J . Disparities in the Use of Sacral Neuromodulation among Medicare Beneficiaries. J Urol. 2015; 194(2):449-53. DOI: 10.1016/j.juro.2015.03.111. View

Dobberfuhl A, Mahal A, Dallas K, Choi K, Comiter C, Elliott C . Statewide Success of Staged Sacral Neuromodulation for the Treatment of Urinary Complaints in California (2005-2011). Female Pelvic Med Reconstr Surg. 2018; 26(7):437-442. DOI: 10.1097/SPV.0000000000000605. View

Manns K, Khan A, Carlson K, Wagg A, Baverstock R, Crump R . The use of onabotulinumtoxinA to treat idiopathic overactive bladder in elderly patients is in need of study. Neurourol Urodyn. 2021; 41(1):42-47. DOI: 10.1002/nau.24809. View

Wang M, Jian Z, Ma Y, Jin X, Li H, Wang K . Percutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis. Int Urogynecol J. 2020; 31(12):2457-2471. DOI: 10.1007/s00192-020-04429-8. View

10.

Amundsen C, Komesu Y, Chermansky C, Gregory W, Myers D, Honeycutt E . Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. Eur Urol. 2018; 74(1):66-73. PMC: 6004242. DOI: 10.1016/j.eururo.2018.02.011. View

11.

Petersen R . Mild Cognitive Impairment. Continuum (Minneap Minn). 2016; 22(2 Dementia):404-18. PMC: 5390929. DOI: 10.1212/CON.0000000000000313. View

12.

Peters K, Kandagatla P, Killinger K, Wolfert C, Boura J . Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology. 2013; 81(4):738-43. DOI: 10.1016/j.urology.2012.11.073. View

13.

Iyer S, Laus K, Rugino A, Botros C, Lozo S, Botros S . Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. Int Urogynecol J. 2018; 30(8):1253-1259. DOI: 10.1007/s00192-018-3822-0. View

14.

Cottrell J, Hartung J . Anesthesia and Cognitive Outcome in Elderly Patients: A Narrative Viewpoint. J Neurosurg Anesthesiol. 2019; 32(1):9-17. PMC: 6919225. DOI: 10.1097/ANA.0000000000000640. View

15.

Palmer C, Nguyen N, Ghoniem G . Clinical experience with percutaneous tibial nerve stimulation in the elderly; do outcomes differ by gender?. Arab J Urol. 2019; 17(1):10-13. PMC: 6583712. DOI: 10.1080/2090598X.2019.1590032. View

16.

Coupland C, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J . Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Intern Med. 2019; 179(8):1084-1093. PMC: 6593623. DOI: 10.1001/jamainternmed.2019.0677. View

17.

Faris A, Gill B, Pizarro-Berdichevsky J, Dielubanza E, Clifton M, Okafor H . Impact of Age and Comorbidities on Use of Sacral Neuromodulation. J Urol. 2017; 198(1):161-166. DOI: 10.1016/j.juro.2017.02.020. View

18.

High R, Winkelman W, Panza J, Sanderson D, Yuen H, Halder G . Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference?. Int Urogynecol J. 2020; 32(1):149-157. DOI: 10.1007/s00192-020-04392-4. View

19.

Miotla P, Cartwright R, Skorupska K, Bogusiewicz M, Markut-Miotla E, Futyma K . Urinary retention in female OAB after intravesical Botox injection: who is really at risk?. Int Urogynecol J. 2016; 28(6):845-850. PMC: 5437187. DOI: 10.1007/s00192-016-3212-4. View

20.

Zillioux J, Slopnick E, Vasavada S . Third-line therapy for overactive bladder in the elderly: Nuances and considerations. Neurourol Urodyn. 2022; 41(8):1967-1974. PMC: 9796112. DOI: 10.1002/nau.24965. View